Board summary
Key figures
44,075
Registered population
59.9% aged 18–64
19.2%
Aged 65+
ICB 20.0% · England 17.9%
9.4%
Ethnic minority (non-White)
7.3% Asian · England 9.6%
26.4%
In IMD quintile 1
ICB 30.6% · England 21.0%
~10,562
Core20 residents (est.)
Resident basis; registered basis ~12,695 · see page 3
7,090
Hypertension register
+9.16% in 3 yrs · England +5.60%
498
SMI register
60.5% of Rossendale's
965
COPD register
Reviews -1.56% in 3 yrs
Forecast to 2030
8,680
Hypertension patients, 2030
+1,590 on today
68.2%
QRISK ≥20% on statins, 2030
+3.08pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure control trails England.
Control in patients under 80 fell 4.2% (England +3.2%) to 61.3% (England 67.8%), whereas control in patients aged 80+ is 82.8% (England 81.2%).
Annual asthma reviews fell over three years.
Coverage fell 9.3% (England +4.4%) to 60.7% (England 65.7%) across 3,133 registered patients, leaving about 1,200 patients without a recorded review.
Frail diabetes control and register growth.
Frail diabetes HbA1c control reaches 83.6% (England 81.9%), non-frail diabetes control rose +11.9% (England +4.4%), and hypertension detection grew +9.2% (England +5.6%).
Population, age and ethnicity
Older residents make up 19.2% of registered patients alongside 22 catchment care homes
Across 44,075 registered patients across six practices, 19.2% (8,467) are aged 65+, compared to 17.6% in Rossendale, 20.0% in NHS Lancashire and South Cumbria Integrated Care Board, and 17.9% in England. Children aged 0-17 make up 20.9% (9,223 patients; Rossendale 21.0%, ICB 19.6%, England 19.6%). Based on Census usual residents rather than GP registrations, 7.3% identify as Asian / Asian British (Rossendale 5.5%, ICB 9.4%, England 9.6%), within a 9.4% non-White share. Population growth is projected at +1.6% to 2030 (Rossendale +1.2%, ICB +1.7%, England +2.3%), though projection methods are unverified.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Rossendale local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rossendale LA) | 1,799 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rossendale LA) | 839 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rossendale LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 26.4% across the PCN and spans 57.7 pp between practices
Across the PCN, 26.4% of registered patients live in Core20 areas, above England (21.0%) but below Rossendale (29.3%) and the ICB (30.6%). Deprivation is sharply uneven, spanning 57.7 pp from 6.4% at St James' Medical Centre to 64.1% at Fairmore Medical Practice. Concentration and volume diverge: Fairmore Medical Practice holds both the highest share and volume (3,921 estimated patients), but Haslingden Healthcare Ltd carries an estimated 2,940 patients at 27.3%. Practice estimates sum to 12,695 against a resident estimate of 10,562, requiring denominator reconciliation before targeting outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
498
SMI register
1.13% recorded prevalence
287
Learning disability register
0.65% recorded prevalence
22
Care homes, 862 beds
In the PCN catchment
9.3%
Provide unpaid care
Rossendale, Census 2021
The PCN records 498 patients on its severe mental illness register (1.1%; Rossendale 1.1%, ICB 1.2%, England 1.0%) and 287 on its learning disability register (0.7%; Rossendale 0.7%, ICB 0.6%, England 0.6%), alongside 22 catchment care homes holding 862 beds.
Severe mental illness: physical health checks
Across published SMI physical-health checks, 80.9% had blood pressure recorded (England 83.4%) and 76.9% had BMI recorded (England 82.1%). Separate recording shows both components trail national levels, leaving scope to systematically close screening gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,090
Hypertension register
+9.16%
Register growth, 3 yrs
Rossendale +7.87% · England +5.60%
−2.68pp
BP control, under 80
≤140/90 · +1.95pp aged 80+
+1,590
More patients by 2030
Forecast 8,680 (19.12%)
Hypertension case-finding and control
The hypertension register grew +9.2% over three years (England +5.6%) to 7,090 patients (16.0%, Rossendale 16.9%, England 15.2%), with 87.8% receiving a recent blood pressure check (England 90.0%). However, blood pressure control in patients aged under 80 fell 4.2% over three years (England +3.2%) to 61.3%, trailing Rossendale (64.2%) and England (67.8%), while overall treatment to target sits at 64.0% (England 70.3%). By contrast, control in patients aged 80 and over reached 82.8% (England 81.2%). This divergence could reflect titration delays, though local clinical audits are needed to test this. Fewer patients under 80 achieve blood pressure control than national benchmarks indicate, making focused titration reviews in under-80 cohorts the immediate priority.
Lipids and statins
For patients with QRISK ≥ 20%, 61.5% receive lipid-lowering therapy, below England (63.6%) and Rossendale (62.6%). Adult lipid-regulating prescribing reaches 2,523 items per 1,000 (England 4,100). Fewer at-risk patients receive lipid-lowering therapy than national rates imply, so systematic recall of eligible patients is the priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 87,942 | £1.60 | £1.64 | £1.86 | £140,707 |
| Cardiovascular (all), 2025 | 127,331 | £3.43 | £3.38 | £3.33 | £436,745 |
In 2026, the PCN prescribed 87,942 items of lipid-regulating drugs at £1.60 per item, below England (£1.86) but above Rossendale (£1.55). Across these items, the PCN spent £22,865 less than at England's unit cost. Lower unit costs than England do not reflect prescribing efficiency or case-mix, requiring local review of therapy choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−9.26%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.64%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.5% across 3,133 registered patients (England 6.6%). Annual asthma reviews fell 9.3% over three years (England +4.4%) to 60.7% (England 65.7%), leaving about 1,200 patients without a recorded review. Furthermore, second-hand smoke status recording in patients aged 6-19 with asthma reached 62.4% (England 78.8%). COPD prevalence sits at 2.2% across 965 patients, where annual reviews fell 1.6% (England +2.8%) to 73.3% (England 76.4%). Declining review rates point to an operational need to audit and restore routine respiratory monitoring.
Cancer register and children's immunisation
The cancer register grew +6.1% over three years (England +9.0%) to 1,727 patients (3.9% vs England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 reached 93.0% at 12 months. At age 5, MMR1 reached 93.0% whereas MMR2 was 82.0% (an 11 pp difference), and the 4-in-1 pre-school booster was 78.1%, below the 95.0% target by 16.9 pp. These cohort contrasts highlight a delivery gap in completing pre-school booster immunisations.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
Across NHS Lancashire and South Cumbria ICB in 2022, 52.4% of cancers with a known stage (4,642 of 8,863 staged cases out of 11,883 registered cancers; known stage 74.6%) were diagnosed at stage 1 or 2, below England (55.3%) and 22.6 pp below the 75.0% national ambition. From 2013 to 2022, this ICB share fell 1.2 pp. In Rossendale West PCN, cervical screening (25-49 years) is 69.2% but fell 3.7% over three years (England -1.0%), and breast screening is 73.3% but fell 0.6% (England +8.4%). Cancer register growth reached +6.1% (England +9.0%). Screening declines may affect early detection, though ICB staging reflects wider system pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Lancashire Hospitals NHS Trust achieved 73.2% against the 85.0% 62-day referral to treatment standard (Northern Care Alliance NHS Foundation Trust 78.6%, Bolton NHS Foundation Trust 69.7%, NHS Lancashire and South Cumbria Integrated Care Board 73.6%, England 71.2%). For the 28-day faster diagnosis standard, East Lancashire reached 81.5% (Bolton NHS Foundation Trust 80.5%, Northern Care Alliance NHS Foundation Trust 75.2%, ICB 78.4%, England 79.3%), above the 75.0% standard. In diagnostics, 32.7% of cystoscopy patients waited 6+ weeks at East Lancashire (England 24.4%), while MRI 6+ week waits were 0.4% (England 21.4%).
| Pathways within standard (%) | East Lancashire | Northern Care Alliance | Bolton | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 75.20 | 80.48 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 94.54 | 96.50 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 78.65 | 69.66 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Northern Care Alliance | Bolton | England |
|---|---|---|---|---|
| MRI | 0.43 | 5.09 | 2.05 | 21.40 |
| CT | 0.15 | 4.10 | 19.40 | 9.92 |
| Echocardiography | 0.00 | 31.48 | 3.48 | 28.48 |
| Colonoscopy | 0.95 | 40.04 | 1.33 | 30.83 |
| Gastroscopy | 1.16 | 36.48 | 2.06 | 29.02 |
| All 15 DM01 tests | 3.25 | 15.71 | 15.78 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026 (provisional), community service contacts for Rossendale borough residents totalled 126,445, with 72,000 contacts involving adults aged 65+, representing 56.9% of all contacts. These figures reflect wider local authority resident activity rather than a PCN cohort, showing substantial community service reliance among older residents.
Practice variation and patient experience
Practice vaccination achievement spans 64.5 pp and phone access varies by 33.5 pp
In 2025/26, QOF overall achievement was 88.4% at Fairmore Medical Practice and 97.6% at Haslingden Healthcare Ltd (England 92.5%). Vaccination and immunisation achievement spans 64.5 pp, with Fairmore Medical Practice achieving 15.6% and Haslingden Healthcare Ltd reaching 80.1% (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Hazelvalley | 90 | 42.7 | 79.2% | 79.1% | 90.7% |
| Haslingden | 110 | 27.3 | 80.5% | 78.0% | 88.4% |
| Ilex View Medical | 105 | 15.2 | 65.1% | 75.0% | 82.3% |
| St James' | 118 | 6.4 | 53.1% | 79.7% | 81.9% |
| Rossendale Valley | 97 | 41.9 | 86.7% | 68.1% | 80.4% |
| Fairmore Medical | 114 | 64.1 | 54.1% | 65.3% | 74.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seventeen of 25 tracked measures trail England trends, led by asthma reviews
Across 25 tracked measures, 17 trail England's three-year change. The largest relative shortfalls are in asthma reviews, falling 9.3% (England +4.4%, a 13.7-point gap), breast screening, down 0.6% (England +8.4%), and blood pressure control in patients under 80, falling 4.2% (England +3.2%). Conversely, key clinical strengths show strong delivery: diabetes HbA1c control without frailty improved +11.9% (England +4.4%), frail diabetes control reached 83.6% (England 81.9%), and smoking cessation offers increased 1.8 pp to 96.6% (England +0.1 pp to 94.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Breast screening (53-70)
Dementia register
BP control, under 80
Hypertension treated to target
Diabetes HbA1c control
Smoking support (SMI)
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rossendale | Asset | PCN | Rossendale |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (862 beds) | n/a | Schools (catchment) | 61 | n/a |
| Children's centres | 3 | 5 | Places of worship | 50 | 44 |
| Libraries | 3 | 4 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 22 | 25 | Primary academies | 2 | 2 |
| Special schools | 2 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and smoke recall
Annual asthma reviews fell 9.3% (England +4.4%) to 60.7% (England 65.7%) across 3,133 patients, leaving 1,232 (about 1,200) unreviewed; youth second-hand smoke recording is 62.4% (England 78.8%). For discussion: practices could run a single-template asthma recall offering after-school slots and combined inhaler and second-hand smoke checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension titration and case-finding
Under-80 BP control fell 4.2% (England +3.2%) to 61.3% (England 67.8%) and treatment to target is 64.0% (England 70.3%); the 7,090 register (16.0%) sits 367 below Rossendale (16.9%) and 377 above England (15.2%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
COPD annual review and register validation
COPD reviews fell 1.6% (England +2.8%) to 73.3% (Rossendale 78.0%, England 76.4%); the crude register of 965 patients (2.2%) sits 178 below Rossendale (2.6%) and 130 above England (1.9%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted cultural access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Blood pressure titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster call-recall audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Screening call-recall and uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review and smoke recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80 hypertension titration and case-finding (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · COPD annual review and register validation (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
